AGE AgeX Therapeutics

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX’s offices are located and where AgeX had planned to hold the Annual Meeting, has issued Health Officer Order 20-21 (the “Order”) restricting or prohibiting many business activities due to the COVID-19 pandemic. The Order provides that offices must close and business must be conducted remotely, except in critical infrastructure sectors where remote work is not possible.

As disclosed in AgeX’s Proxy Statement, AgeX has made arrangements for stockholders to attend and vote at the Annual Meeting online. Stockholders who follow the procedures for attending the Annual Meeting online will be able to vote at the Annual Meeting and ask questions. If you do not comply with the procedures for attending the Annual Meeting online, you will not be able to participate and vote at the Annual Meeting online but you may view the Annual Meeting webcast by visiting and following the instructions to log in as a guest using the password agex2020.

If you are a “stockholder of record” (meaning that you have a stock certificate registered in your own name), to attend and participate in the Annual Meeting online you will need to visit and use the control number on your proxy card to log on. The password for the Annual Meeting is agex2020.

If you are a “street name” stockholder (meaning that your shares are held in an account at a broker-dealer firm) and you wish to participate and vote online at the Annual Meeting, you must first obtain a valid legal proxy from your broker, bank or other agent and then register in advance to attend the Annual Meeting by following the directions for registration in section of AgeX’s Proxy Statement entitled “HOW TO ATTEND THE ANNUAL MEETING”.

Please refer to your copy of the Proxy Statement for the Annual Meeting for other information about the Annual Meeting and matters proposed to be approved by AgeX stockholders at the Annual Meeting. A copy of the Proxy Statement and other proxy materials and our Annual Report on Form 10-K, as amended, can also be found at and on the SEC’s website at and in the “Investors-Financial Information-SEC Filings” portion of AgeX’s website at .

If you cannot participate online you may still vote your shares by submitting a proxy by mail, by phone, or online by following the instructions on your proxy card.

EN
22/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AgeX Therapeutics

 PRESS RELEASE

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Regi...

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ - HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates ena...

 PRESS RELEASE

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Regis...

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing in the first quarter of 2026 HUNTSVILLE, AL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its propriet...

 PRESS RELEASE

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A W...

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"  Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sectorMeet with Serina’s CEO Steven LedgerRegister at HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing ...

 PRESS RELEASE

Serina Therapeutics Announces FDA Clearance of IND Application for SER...

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease - Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

 PRESS RELEASE

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Sh...

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's listing st...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch